GAHI is based at LSHTM, a world-leading centre for research and postgraduate education in public and global health, with a mission to improve health and health equity in the UK and worldwide. The School has a long history working with NTDs, and is home to several world-leading NTD research groups.
The Partnership for Child Development (PCD), based at Imperial College London, is a global partnership of civil society organisations, academic institutions and technical experts committed to improving the education, health and nutrition of school-aged children and youth in low- and middle-income countries.
Children Without Worms (CWW) is a partnership between Johnson & Johnson and the Task Force for Global Health in the global control of soil-transmitted helminths (STH). CWW envisions the world's children free of STH so they can grow, play, learn and enrich their communities.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GSK is an active partner in the WHO-led effort to eliminate lymphatic filariasis and in late 2010 announced a new five year commitment to expand its albendazole donation programme to treat children at risk of soil-transmitted helminths.
The Global Atlas of Trachoma (GAT) provides updated and publicly accessible country maps of the geographic distribution of trachoma.
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research. The Department of Infectious Disease Epidemiology houses the world’s largest and leading concentration of scientists working on translating epidemiological theory into health policy, including the Helminth Ecology group and the Schistosomiasis Research group.
The International Trachoma Initiative (ITI) coordinates the donation of Zithromax® by Pfizer and collaborates with governmental and nongovernmental agencies at the local, national and international levels to implement the WHO-recommended SAFE strategy for trachoma control.
The Kenya Medical Research Institute (KEMRI) is one of the leading health research institutes in Africa with demonstrated success in conducting world-leading, high impact collaborative biomedical research. The Institute is home to the NTD department at the Eastern and Southern African Centre for Parasite Control (ESACIPAC).
The London Centre for NTD Research is a joint initiative of Imperial College London, the London School of Hygiene & Tropical Medicine and the Natural History Museum. The Centre undertakes cutting-edge research to build the evidence base around the design, implementation and evaluation of NTD control and elimination programmes.
The Mectizan Donation Program provides support control and elimination initiatives for onchocerciasis and lymphatic filariasis through the co-administration of Mectizan and albendazole, donated by GlaxoSmithKline. Currently, more than 70 million treatments are approved yearly for onchocerciasis and 80 million for LF.
RTI International is one of the world’s leading research institutes, dedicated to improving the human condition by turning knowledge into practice. RTI is also a global leader in NTD control and elimination. Since 2006, they have worked in close partnership with 23 NTD endemic countries to help integrate and scale up national programs for lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths and trachoma.
The Schistosomiasis Control Initiative (SCI) provides technical assistance to national schistosomiasis and STH control programmes. SCI is located within Imperial College London, where it combines implementation with world-class research to ensure treatment programmes achieve maximum effectiveness.
Both WHO Geneva and the WHO regional office for Africa (WHO-AFRO) have provided key support to the project. The Department of Neglected Tropical Diseases helped establish the project and has provided guidance to the overall design of the project and access to data. WHO-AFRO has also contributed technical input and information.
